News

EastGroup Properties Q3 2024 Performance Shows Continued Growth

EastGroup Properties Q3 2024 Performance Shows Continued Growth

EastGroup Properties Reports Strong Third Quarter 2024 Results

Key Highlights from Q3 2024

  • Net Income attributable to common stockholders of $1.13 per diluted share, up from $1.07 in Q3 2023.
  • Funds from Operations (FFO) reached $2.13 per share, marking a 9.2% increase compared to the prior year's third quarter.
  • Same Property Net Operating Income increased by 5.5% on a straight-line basis and 5.9% on a cash basis, compared to Q3 2023.
  • Leasing metrics remained strong, with 96.9% of the operating portfolio leased as of September 30, 2024.
  • Average rental rates on new and renewal leases surged by 50.9% on a straight-line basis.
  • Acquisition of an operating property comprising 179,000 square feet for about $36 million.
  • Initiated two development projects totaling 310,000 square feet with an estimated total cost of approximately $40 million.
  • A total of three development projects comprising 735,000 square feet transferred to the operating portfolio.

In reflecting on EastGroup's performance, CEO Marshall Loeb stated that the quarter’s results underscore the resilience of their portfolio amid a fluctuating leasing environment. The company is showing a steady performance across various metrics, and Loeb expressed optimism about the company’s position to leverage future growth opportunities.

Earnings Overview

Three Months Ended September 30, 2024:

On a diluted basis, the earnings per share (EPS) for the three months was $1.13, compared to $1.07 for the same period in 2023. This rise in EPS was primarily due to a property net operating income (PNOI) increase of $15,029,000 (or $0.31 per share).

  • However, this increase was partially offset by depreciation and amortization expenses, which climbed by $6,396,000 ($0.13 per diluted share) for the same period.
  • Furthermore, a rise in weighted average shares diluted by 3,211,000 shares added to the expenses.

Nine Months Ended September 30, 2024:

Compared with last year, the diluted EPS increased to $3.49 in the first nine months of 2024, up from $3.06 in 2023. This growth was driven by a PNOI rise of $40,759,000 ($0.84 per share) and an increase in gains from real estate sales:

  • Real estate sales generated gains of $8,751,000 ($0.18 per share) during this nine-month period, up from $4,809,000 ($0.11 per share) last year.
  • Interest expenses also saw a decrease of $7,124,000 ($0.15 per share), contributing positively to the financial standing of the company.

Funds from Operations and PNOI Insights

For the three months ending September 30, 2024, FFO attributable to common stockholders stood at $2.13 per share, representing a 6.5% increase from $2.00 per share during the same period in 2023.

When excluding gains related to involuntary conversions or business interruption claims, FFO also increased by 9.2%, from $1.95 to $2.13 per share.

The report indicates that the PNOI rose by $15,029,000 or 14.5% during the quarter in comparison to the last year. The sources of this increase were attributed to:

  • Same property operations contributing approximately $6,917,000.
  • Newly developed and value-added properties adding approximately $4,897,000.
  • Acquisitions contributing around $3,978,000.
  • However, sales of operating properties during 2023 and 2024 resulted in a $792,000 decrease.

Acquisitions and Development Projects

EastGroup Properties acquired two industrial properties totaling 179,000 square feet for approximately $35,781,000, further sharpening their footprint in the industrial market.

As of the current quarter, EastGroup is actively involved in 17 developmental projects managing a total of 3,698,000 square feet across 12 strategic markets.

Within the nine months, these projects have been demonstrated with the capacity of 31% leasing and are projected to incur around $527,700,000 in total costs.

Dividends and Financial Strength

The company declared a cash dividend of $1.40 per share in Q3 2024, marking an impressive 10.2% increase from the prior quarter. This amount symbolizes the company's dedication to its shareholders with a string of consecutive increases in dividend payments over the past decades.

EastGroup fosters a robust financial performance, maintaining a debt-to-total market capitalization at 15.1% as of September 30, 2024, enhancing confidence in its ability to sustain positive operations.

Outlook for 2024

Based on recent performances, EastGroup anticipates EPS for 2024 to fall within $4.64 to $4.68, while FFO per share estimates align between $8.33 to $8.37. These projections, reflecting a deep analysis by the management, are subject to the underlying economic and operational trends.

Frequently Asked Questions

What were the key highlights from EastGroup's Q3 2024 report?

EastGroup announced a net income of $1.13 per diluted share and a 9.2% increase in FFO, showcasing strong performance metrics across various areas.

How has EastGroup's occupancy rate changed in the recent quarter?

The company's operating portfolio was 96.9% leased and 96.5% occupied, indicating minor fluctuations compared to previous periods.

What new projects are EastGroup developing?

EastGroup started two development projects totaling 310,000 square feet with projected costs around $40 million, enhancing its market presence.

How does EastGroup ensure dividend growth for its shareholders?

EastGroup maintains a strategy of increasing or maintaining dividends annually, having a record of 32 consecutive years.

What financial metrics does EastGroup prioritize for assessing performance?

EastGroup focuses on funds from operations (FFO) and property net operating income (PNOI) as primary measures for evaluating business operations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

BioCryst Pharmaceuticals Reports Positive Outcomes for ORLADEYO

Updated Category News Views 62

BioCryst Pharmaceuticals Highlights ORLADEYO's Impact BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has unveiled a compelling study that underscores how ORLADEYO (berotralstat) significantly lowers healthcare resource utilization (HRU) for patients battling hereditary angioedema (HAE). This innovative oral treatment has garnered attention due to its remarkable findings,...

Continue Reading
Man Group PLC Discloses Interest in Spectris plc Shares

Updated Category News Views 174

Understanding Man Group PLC's Position Disclosure Man Group PLC is making headlines as it officially discloses its holdings in Spectris plc. This disclosure is known as FORM 8.3 and is a crucial document under Rule 8.3 of the Takeover Code. It indicates the shareholding interests of Man Group in Spectris, representing a significant percentage of the company's relevant...

Continue Reading
Centessa Pharmaceuticals Seeks $225 Million Through Public Offering

Updated Category News Views 91

Centessa Pharmaceuticals Launches Major $225 Million Offering Centessa Pharmaceuticals plc (NASDAQ: CNTA), an innovative clinical-stage pharmaceutical company, has announced an ambitious public offering with the goal of raising around $225 million. This offering features 15,254,237 American Depositary Shares (ADSs), each representing one ordinary share, priced at $14.75...

Continue Reading
Unveiling Software Giants: Microsoft and Its Rivals in 2024

Updated Category News Views 350

Understanding the Competitive Landscape of Software Giants In the dynamic world of software, staying informed about leading companies is vital for investors and analysts alike. This article focuses on Microsoft (NASDAQ: MSFT) and its primary competitors, aiming to deliver a thorough analysis of financial statistics, market standings, and opportunities for growth within...

Continue Reading
Harris Leads Trump by 3 Points in Key Election Polls

Updated Category News Views 105

Election Polls Show Harris's Slim Lead Over Trump In the battleground of the upcoming U.S. presidential election, Democratic Vice President Kamala Harris has established a slender lead over Republican contender Donald Trump, according to the latest polling data. Recent surveys indicate that Harris is ahead by a margin of 3 points, with her support reaching 45% compared to...

Continue Reading